Avatar photo

Dr Romero Gomez

Dr. Manuel Romero Gómez is a renowned hepatology expert and Full-Professor of Medicine at the University of Seville, Spain. As the Chief of the Digestive Diseases Department at Virgen del Rocío University Hospitals, he leads significant research projects in liver diseases. With over 340 publications and numerous awards, Dr. Romero Gómez is a prominent figure in the field of gastrointestinal and liver diseases.
Prof.-Manuel-Romero-Gomez

The Course of Liver Histology and Morbi-Mortality in NAFLD / NASH

Prof. Manuel Romero-Gomez discusses the course of liver histology and its impact on mortality and morbidity in patients with NAFLD and NASH. He clarifies how fibrosis determines the prognosis of NAFLD and is the main therapeutic target. The importance of steatosis is also discussed both at the early phase and advanced phase. Finally he reviews the association with HCC and CV risks.
Read MoreThe Course of Liver Histology and Morbi-Mortality in NAFLD / NASH
Prof.-Manuel-Romero-Gomez

IMAGING BIOMARKERS IN NAFLD: COULD THEY AVOID LIVER BIOPSY?

The diagnosis of NASH is critically important for clinical trials and clinical practice. Today, the gold standard to diagnose NASH is a liver biopsy, as it’s the most complete diagnostic solution allowing clinicians to study key characteristics of the disease. But it has limitations. Liver biopsies require significant expertise both to perform but also to interpret the results. Biomarkers could play an important role and imaging biomarkers (transient elastography and shear-wave) plus MRI techniques allow assessment of liver damage in NAFLD with high diagnostic accuracy
Read MoreIMAGING BIOMARKERS IN NAFLD: COULD THEY AVOID LIVER BIOPSY?
Prof.-Manuel-Romero-Gomez

Imaging biomarkers in NAFLD: Could they avoid liver biopsy

There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm
Read MoreImaging biomarkers in NAFLD: Could they avoid liver biopsy

Dr. Manuel Romero Gómez has established a distinguished career in the field of hepatology and gastrointestinal diseases. As a Full-Professor of Medicine at the University of Seville, Spain, and Chief of the Digestive Diseases Department at Virgen del Rocío University Hospitals, he has contributed significantly to research and education in the field. His leadership roles include heading a translational research group in liver diseases at the Institute of Biomedicine of Seville, as well as being involved in numerous European projects focused on liver disease.

Education and Professional Background

  • Full-Professor of Medicine at the University of Seville, Spain.
  • Chief of the Digestive Diseases Department, Virgen del Rocío University Hospitals.

Research and Leadership

  • Head of group for translational research in liver diseases at the Institute of Biomedicine of Seville and Spanish Network for Research in Digestive and Liver Diseases (CiberEHD).
  • Leader of Sub-project 7 for the European Project FLIP (Fatty Liver Inhibition of Progression).
  • National leader of LITMUS project.
  • Co-coordinator of European NAFLD Registry funded by EASL.

Awards and Recognition

  • Member of the Strategic for Research Plan in Andalusia.
  • Recipient of the XI Award Javier Benjumea Puigcerver in investigation, Universidad de Sevilla-Focus Abengoa, 2014.

Publications and Innovations

  • Published over 340 peer-reviewed papers on gastrointestinal and liver diseases.
  • Directed more than 24 publicly-funded research projects.
  • Protected 10 different patents.

Dr. Romero Gómez has received recognition for his work, including the XI Award Javier Benjumea Puigcerver in investigation, awarded by Universidad de Sevilla-Focus Abengoa in 2014. He is also a member of the Strategic for Research Plan in Andalusia. His extensive research has resulted in over 340 peer-reviewed publications, the direction of more than 24 publicly-funded research projects, and the protection of 10 different patents.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES